Verve Therapeutics, Inc. VERV
We take great care to ensure that the data presented and summarized in this overview for Verve Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERV
View all-
Alphabet Inc. Mountain View, CA12.2MShares$135 Million8.86% of portfolio
-
Pentwater Capital Management LP Naples, FL6.72MShares$74.8 Million0.5% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$73.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.19MShares$46.7 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4.1MShares$45.6 Million6.45% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.61MShares$40.2 Million0.18% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ2.74MShares$30.5 Million1.68% of portfolio
-
State Street Corp Boston, MA2.63MShares$29.2 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL2.01MShares$22.4 Million11.95% of portfolio
-
Ubs Group Ag1.87MShares$20.8 Million0.0% of portfolio
Latest Institutional Activity in VERV
Top Purchases
Top Sells
About VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VERV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 25
2025
|
Jason Politi Chief Technical Ops. Off. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,405
-100.0%
|
-
|
|
Jul 25
2025
|
Andrew D. Ashe |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
348,828
-100.0%
|
-
|
|
Jul 25
2025
|
Burt A Adelman |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
428,326
-100.0%
|
-
|
|
Jul 25
2025
|
Troy Lister Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,952
-100.0%
|
-
|
|
Jul 25
2025
|
Sekar Kathiresan Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
351,994
-100.0%
|
-
|
|
Jul 25
2025
|
Sekar Kathiresan Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
348,431
-100.0%
|
-
|
|
Jul 25
2025
|
Joan Nickerson Chief Administrative Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,420
-100.0%
|
-
|
|
Jul 25
2025
|
Allison Dorval Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,280
-100.0%
|
-
|
|
Jul 25
2025
|
Krishna Yeshwant |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
12,168,489
-100.0%
|
-
|
|
Jul 25
2025
|
Gv 2017 Gp, L.L.C. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
12,168,489
-100.0%
|
-
|
|
Apr 02
2025
|
Troy Lister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,189
-23.95%
|
$8,756
$4.15 P/Share
|
|
Apr 02
2025
|
Allison Dorval Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,350
-20.14%
|
$13,400
$4.15 P/Share
|
|
Apr 02
2025
|
Jason Politi Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
3,235
-18.53%
|
$12,940
$4.15 P/Share
|
|
Apr 02
2025
|
Andrew D. Ashe |
SELL
Open market or private sale
|
Direct |
2,681
-0.76%
|
$10,724
$4.15 P/Share
|
|
Apr 02
2025
|
Joan Nickerson Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
2,777
-13.75%
|
$11,108
$4.15 P/Share
|
|
Apr 02
2025
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,822
-2.76%
|
$39,288
$4.15 P/Share
|
|
Apr 01
2025
|
Troy Lister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,340
+44.54%
|
-
|
|
Apr 01
2025
|
Allison Dorval Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+40.35%
|
-
|
|
Apr 01
2025
|
Jason Politi Chief Technical Ops. Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
8,815
+33.55%
|
-
|
|
Apr 01
2025
|
Andrew D. Ashe |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+2.5%
|
-
|
Last 12 Months Summary
| Bona fide gift | 30K shares |
|---|---|
| Exercise of conversion of derivative security | 80.6K shares |
| Disposition due to a tender of shares in a change of control transaction | 25.9M shares |
|---|---|
| Bona fide gift | 30K shares |
| Open market or private sale | 24.6K shares |